HYALGAN[®] REIMBURSEMENT IN THE HOSPITAL OUTPATIENT SETTING

CODING

Codes relevant to HYALGAN[®] and its administration in the hospital outpatient setting are described in the following section. For more information on reporting various codes in the hospital outpatient site of care, please refer to the sample CMS-1450/UB-04 claim form for HYALGAN[®] therapy on page 16.

Note: While the general codes relevant to HYALGAN® therapy in the hospital outpatient setting are noted in this section, other codes beyond those listed here may also be considered appropriate. As coverage for codes may vary by payer, please call the *HYALGAN® Support Hotline* at **1.866.7.HYALGAN** (1.866.749.2542), Monday to Friday, from 9:00 AM to 8:00 PM EST for assistance to verify specific or unique payer coding requirements.

On a CMS-1450/UB-04 claim form, applicable ICD-10-CM diagnosis codes must be reported in Box 66.

ICD-10	Description
M17.0	Bilateral primary osteoarthritis of knee
M17.10	Unilateral primary osteoarthritis, unspecified knee
M17.11	Unilateral primary osteoarthritis, right knee
M17.12	Unilateral primary osteoarthritis, left knee
M17.2	Bilateral post-traumatic osteoarthritis of knee
M17.30	Unilateral post-traumatic osteoarthritis, unspecified knee
M17.31	Unilateral post-traumatic osteoarthritis, right knee
M17.32	Unilateral post-traumatic osteoarthritis, left knee
M17.4	Other bilateral secondary osteoarthritis of knee
M17.5	Other unilateral secondary osteoarthritis of knee
M17.9	Osteoarthritis of knee, unspecified



HCPCS

To report HYALGAN[®] administration in the hospital outpatient setting, use of the HYALGAN[®] permanent HCPCS code is appropriate, as noted below:

HCPCS Code	Description
J7321	Hyaluronan or derivative, HYALGAN®, for intra-articular injection, per dose

On a CMS-1450/UB-04 claim form, Box 44 and Box 46 should be used for reporting the HYALGAN[®] permanent HCPCS code and the number of units administered, respectively.

СРТ

To report the physician administration of HYALGAN[®], the following CPT code may be appropriate when HYALGAN[®] is administered in the hospital outpatient setting:

СРТ	Description
20610	Arthrocentesis, aspiration and/or injection; major joint or bursa (eg, shoulder, hip, knee joint, subacromial bursa), without ultrasound guidance
20611	Arthrocentesis, aspiration and/or injection, major joint or bursa (eg, shoulder, hip, knee, subacromial bursa); with ultrasound guidance, with permanent recording and reporting

CPT codes should be reported in Box 44 of the CMS-1450/UB-04 claim form as well.

MODIFIERS: In certain instances, payers may require modifier "-RT" (right side) or "-LT" (left side) to be documented after CPT code 20610/20611, to specify which knee HYALGAN[®] was administered to. For bilateral administration of HYALGAN[®], some payers may require modifier "-50" (bilateral procedure) to be documented after CPT code 20610/20611.

Use "EJ" modifier on drug codes to indicate subsequent injections of a series. Do not use this modifier for the first injection of each series of injections. A series is defined as the set of injections for each joint and each treatment. Injection of the left knee is a separate series from injection of the right knee.

Revenue Codes

When prescribing HYALGAN[®] therapy within the hospital outpatient setting, revenue codes may also be used to report services and supplies that are utilized during treatment.

Revenue Code	Description				
0636	Drugs requiring detailed coding				
0510	Clinic, general				

On the CMS-1450/UB-04 claim form, revenue codes should be documented in Box 42. Revenue code 0636, however, must be listed as the same reporting line as J7321 (HYALGAN®), since it describes detailed coding for drugs/products.



HYALGAN® CMS-1450/UB-04 SAMPLE CLAIM FORM

		1				2					3a F CNT	PAT. 1 #				4 1	YPE BILL
	1										b. M REC	ED.					
												ED. TAX NO.	6 S F	TATEMENT COVER	rs Period Through	7	
																1	
	1	8 PATIENT N	AME a				9 PATIENT ADD	RESS	а								
		ь					b							c d		е	
		10 BIRTHDAT	E 11 SEX	12 DATE	DMISSION 13 HR 14 TYP	E 15 SRC 16 DHR	17 STAT 18	19	20 2	CONDIT 22	10N CODE 23	S 24 25	26 27	28 29 ACD STATE	T 30		
		at 0000	PPENCE 20	OCCURRENCE	22 00	CURRENCE		ENCE	0.5	OCCUPE	ENCE SPA	N			N	07	
		31 OCCU CODE	RRENCE 32 DATE COD	OCCURRENCE E DATE	33 OC CODE	DATE	34 OCCURR CODE	DATE	35 CODE	FROM	ENCE OPA	THROUGH	36 O CODE	CCURRENCE SPAI	THROUGH	3/	
											_					4	_
		38							3	9 VA	LUE CODE	Box 46	: Service	Units		UE CODES	
					4: HCPCS				a	9 VA ODE	AMOUNT			ALGAN [®] units	s	AMOUNT	
						e for HYALGAN rivative, HYAL			b			administ	tered				
						ection, per do			с			Evample	· 1 service i	init for each	dose		
							_		d			Example		interior edent	4050		
	1	42 REV. CD.	43 DESCRIPTION				44 HCPCS / ATE	/ HIPPS CODE		45 SERV. D	ATE	46 SEL UNITS	47 TOTAL	CHARGES	48 NON-COVE	ERED CHARGES	49
	1	0636	Drugs requiri	ng detail info	ormation (H	YALGAN)	J7321			MMC	DYY	x		XX,XX			1
	2	0510	Clinic visit (k	nee joint inje	ection in clir	nic)	2060 - !	50		MMC	DYY	1		XX.XX			2
	-																3
Fields 42-4	3: E	nter the a	pppropriate														4
revenue co							Box 44:					_					5
	ling	to the HC	PCS code in				Enter app	propriate	CPI COC	e and mo	aitier						6
Field 44 - 0636 for H		GAN®					Example:	20610-	Arthroce	ntesis,							ľ.
- 0510 for k			ction				aspiratio										
			atient clinic				or bursa subacron			, knee joi	nt,						10
Noto: Otho	r rov	ionuo cod	es may apply				Subacton	mat burs	aj								11
Note. Othe	iiev	enue cou	es may apply														12
	13																13
	14																14
	15																15
	16																16
	17																17
	18																18
	19																19
	21																21
	22																22
	23		PAGE	OF			CR	EATIOI	V DATE	-		TOTALS			-		23
	1	50 PAYER N			-	51 HEALTH PLAN ID		52 RE		4 PRIOR PAY	MENTS	55 EST. AMC	OUNT DUE	56 NPI			
														57			A
	в													OTHER			в
	c													PRV ID			c
		58 INSURED	'S NAME			59 P. REL 6	0 INSURED'S UNI	que id			61 GR	DUP NAME		62 INSURANC	CE GROUP NO.		
	٨																Â
				4.44													в
			lentify the type ode used	of ICD		Fields	67 and 67A-	67Q: Eni	ter				65 EMPLOYER 1	IAME			ĭ
	u	lagilo313 C	.oue useu				riate ICD-10						OD EMP COTENT	Punt.			
	- 1	Enter a "()" for ICD-10-CM	1			Bilateral prin pecific 4th a										8
							dical record			ena							c
		M 📩	17.0									F	G		61	3	
		0		J		Note: C	ther diagno	ses code	es may ap	ply		0	Р	G			
		69 ADMIT DX	7 R	PATIENT EASON DX	a	17		00	E	ECI					73		
			RINCIPAL PROCEDUR	E a.	CODE	DCEDURE	b. OT CODE	HER PROCE	DURE	75			NPI		QUAL		
		3EOL	OTHER PROCEDURE	d.	OTHER DR	OCEDURE	a 01	HER DROCE	DURE		LAS			FI	IRST		
		<u> </u>	OTHER PROCEDURE	E a.	CODE	DCEDURE DATE	CODE	HER PROCE	DATE				NPI		QUAL		
		en PE		nel Deres		0 Det					LAS		NDI	F	IRST OLIAL		
		BOX 74: Principal Procedure Code & Date Enter principal ICD-10-PCS procedure code and date										78 OTHER NPI OUAL LAST FIRST					
	Enter principarios-10-PCS procedure code and date											FIRST QUAL					
			ample: 3E0U3G		aneous kne	e joint injecti	on				LAS			FI	IRST		
		_{UB-04} Of	a therapeutic s	ubstance									S ON THE REVER	ISE APPLY TO THIS			
																NUBC	lational Uniform illing Committee 09/21/32/57
	_																

DISCLAIMER: HYALGAN® Sample Claim Form CMS-1450/UB-04 is intended solely for use as a resource tool to assist physician office and hospital outpatient billing staff regarding reimbursement issues. Any determination about if and how to seek reimbursement should be made only by the appropriate members of the physician office or hospital outpatient staff in consultation with the physician and in consideration of the procedure performed or therapy provided to a specific patient. FIDIA FARMACEUTICI S.P.A/FIDIA PHARMA USA INC. do not recommend or endorse the use of any particular diagnosis or procedure code(s) and makes no determination if or how reimbursement may be available. Of important note, reimbursement codes and payment, as well as health policy/legislation are subject to continual change; information contained in this version of the HYALGAN® Reimbursement Guide is current as of January 2020.



PAYMENT

The following section describes public (Medicare/Medicaid) and private payer payment information relevant to HYALGAN[®] and its administration in the hospital outpatient setting.

Note: Because of variability in payment across Medicaid and private payer plans, it is particularly important to conduct patient-specific insurance benefit verifications for HYALGAN® therapy for patients with these types of healthcare insurance. To contact a reimbursement specialist for conducting patient-specific insurance benefit verifications, please call the *HYALGAN® Support Hotline* at **1.866.7.HYALGAN (1.866.749.2542)**, Monday to Friday, from 9:00 AM to 8:00 PM EST.

Medicare

When HYALGAN[®] is injected in the hospital outpatient setting, Medicare may reimburse both the product and services associated with its administration. The payment methodology for HYALGAN[®] in 2018 is based on its ASP plus 6%^{*}. Please note that Medicare's drug and product payment rates change on a quarterly basis. In addition services that are associated with HYALGAN[®] administration would be reimbursed based on the Hospital Outpatient Prospective Payment System (HOPPS or Ambulatory Payment Classification (APC) system. Specifically, under the APC system, each APC is associated with a fixed reimbursement amount that the hospital receives, regardless of the actual cost incurred.

Physician reimbursement in the hospital outpatient setting:

СРТ	Description
20610	Arthrocentesis, aspiration and/or injection; major joint or bursa (eg, shoulder, hip, knee joint, subacromial bursa), without ultrasound guidance
20611	Arthrocentesis, aspiration and/or injection, major joint or bursa (eg, shoulder, hip, knee, subacromial bursa); with ultrasound guidance, with permanent recording and reporting

In general, Medicare pays 80% of the allowed amount of the drug/product and service. Medicare beneficiaries are responsible for 20% of the allowed amount of the drug/product and service once a deductible has been met. If a Medicare beneficiary has a source of secondary coverage, that insurance may be used toward this cost-sharing requirement

* This allowed payment is subject to change.



Private Payers

Private payers typically negotiate payment rates for HYALGAN[®] when administered in the hospital outpatient setting that may be based on a fee schedule, a percentage of billed or allowable charges, or a percentage of WAC or ASP. For each patient, cost-sharing requirements, such as coinsurance and annual deductible amounts, will vary by individual insurance plan.

Medicaid

State Medicaid programs have different payment rates for HYALGAN[®] when administered in the hospital outpatient setting. Specifically, payment for HYALGAN[®] and its associated administration services may be based on state-specific fee-for-service schedules, preset rates, or a percentage of charges. In the hospital outpatient setting, HYALGAN[®] may be reimbursed based on other methodologies such as a percentage of WAC or invoice price. Certain state Medicaid programs may require nominal cost-sharing by Medicaid beneficiaries for drugs/products and services.

